Clover Biopharmaceuticals (HKSE:02197) Total Equity: HK$-1,985.54 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02197 Clover Biopharmaceuticals Ltd HKSE:02197
28 GF Score
Price HK$2.37
! 3 Warning Signs
View Full Analysis

What is Clover Biopharmaceuticals Total Equity?

Clover Biopharmaceuticals HKSE:02197 -6.88% 28 Total Equity is HK$-1,985.54 Mil as of Dec. 2025. GuruFocus rates HKSE:02197 with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Clover Biopharmaceuticals's total equity for the quarter that ended in Dec. 2025 was HK$-1,985.54 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Clover Biopharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Clover Biopharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clover Biopharmaceuticals Total Equity Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 1,492.81 -746.12 -801.56 -1,747.03 -1,985.54

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -801.56 -896.52 -1,747.03 -1,864.89 -1,985.54
HKSE:02197
28GF Score
Clover Biopharmaceuticals Ltd HKSE:02197
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clover Biopharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Clover Biopharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=505.877-2491.42
=-1,985.54

Clover Biopharmaceuticals's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=505.877-2491.42
=-1,985.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$-1,985.54 Mil mean?
Clover Biopharmaceuticals (HKSE:02197) has a Total Equity of HK$-1,985.54 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Clover Biopharmaceuticals and its competitors.
Is Clover Biopharmaceuticals' Total Equity too high?
Clover Biopharmaceuticals' current Total Equity is HK$-1,985.54 Mil. Overall, Clover Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Clover Biopharmaceuticals' Total Equity compare to VRTX and REGN?
Clover Biopharmaceuticals' Total Equity of HK$-1,985.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Clover Biopharmaceuticals and its competitors. Clover Biopharmaceuticals's current Total Equity is HK$-1,985.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Biopharmaceuticals stock overvalued right now?
Clover Biopharmaceuticals (HKSE:02197) has a current Total Equity of HK$-1,985.54 Mil. The current Total Equity is HK$-1,985.54 Mil. Clover Biopharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Clover Biopharmaceuticals (HKSE:02197), the current Total Equity is HK$-1,985.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clover Biopharmaceuticals Business Description

Address No. 758 West Nanjing Road, Room 1901, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
28GF Score

Get the complete analysis for HKSE:02197

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.37
Price